BioNTech SE (FRA:22UA)
73.75
-1.50 (-1.99%)
At close: Mar 27, 2026
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
€367,606
Profits / Employee
€145,523
Market Cap
17.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 177,356 |
| Fresenius Medical Care AG | 109,698 |
| Bayer Aktiengesellschaft | 87,280 |
| Siemens Healthineers AG | 73,800 |
| Merck KGaA | 59,077 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 14,042 |
| Ottobock SE & Co. KGaA | 9,256 |
BioNTech SE News
- 5 days ago - BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer - GlobeNewsWire
- 13 days ago - BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity. - Barron's
- 18 days ago - Moderna (MRNA) and BioNTech (BNTX) Shares Rise on Advisory Reversal - GuruFocus
- 18 days ago - Morgan Stanley Lowers Price Target for BioNTech (BNTX) to $125 | BNTX Stock News - GuruFocus
- 18 days ago - Canaccord Genuity Reiterates Buy Rating for BioNTech (BNTX) at $171 PT | BNTX Stock News - GuruFocus
- 18 days ago - BioNTech (BNTX): Citigroup Maintains 'Buy' but Slashes Price Target | BNTX Stock News - GuruFocus
- 18 days ago - BioNTech (BNTX) Reports Q4 Loss of EUR0.33/Share as COVID Vaccine Revenue Plunges; Founders Exit - AlphaStreet
- 18 days ago - TD Cowen Maintains Hold Rating on BNTX, Lowers Price Target | BNTX Stock News - GuruFocus